RayKnowChina Research Map
Shortlist0

Not yet recruitingHepatocellular carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Nanfang Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorNanfang Hospital南方医科大学南方医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07565415, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Child-Pugh score ≤ 7

    Inclusion criterion 3

  3. At least one measurable lesion per RECIST 1.1 criteria; lesions without prior radiotherapy, cryotherapy or other local treatment

    Inclusion criterion 4

    Fertile male and female patients agree to effective contraception from screening to 120 days after last study drug

    Inclusion criterion 21

    Unresolved adverse toxicities from prior antitumor therapy not recovered to ≤ Grade 1 (CTCAE v5.0), excluding alopecia

    Exclusion criterion 5

  4. ECOG performance status 0 or 1

    Inclusion criterion 11

  5. Hematology: ANC ≥ 1.5×10⁹/L, Hb ≥ 80 g/L, PLT ≥ 50×10⁹/L

    Inclusion criterion 14

    Liver function: TBIL ≤ 1.5×ULN, AST/ALT ≤ 5.0×ULN, ALB ≥ 28 g/L

    Inclusion criterion 15

    Coagulation function: INR, PT or aPTT ≤ 1.5×ULN

    Inclusion criterion 16

    Renal function: SCr ≤ 1.5×ULN or creatinine clearance ≥ 60 mL/min

    Inclusion criterion 17

  6. History of other malignancies within 5 years before randomization, except curable low-risk tumors

    Exclusion criterion 4

    Positive HIV infection

    Exclusion criterion 8

  7. Females of childbearing potential with negative pregnancy test within 3 days before first dosing

    Inclusion criterion 20

    Pregnant, breastfeeding females or those planning pregnancy during the study

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07565415, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients with unresectable primary hepatocellular carcinoma (HCC) confirmed by imaging or histopathology
  • No previous receipt of immunotherapy and/or targeted drug therapy
  • Child-Pugh score ≤ 7
  • At least one measurable lesion per RECIST 1.1 criteria; lesions without prior radiotherapy, cryotherapy or other local treatment
  • Single intrahepatic lesion < 10 cm, or fewer than 10 intrahepatic lesions with tumor burden < 50%
  • Meet precachexia criteria: non-volitional weight loss ≤ 5% in 6 months, plus systemic inflammation (CRP > 5 mg/L) or decreased appetite (FAACT-A/CS-12 score ≤ 37 points)
  • Meet cachexia criteria: accompanied by decreased appetite or systemic inflammation, with either non-volitional weight loss > 5% in 6 months or BMI < 18.5 kg/m² plus weight loss > 2%
  • Voluntarily participate and sign informed consent
  • Age ≥ 18 years, male or female
  • Able to swallow tablets normally
  • ECOG performance status 0 or 1
  • Life expectancy ≥ 12 weeks
  • Adequate major organ function without blood products or colony-stimulating factors within 14 days
  • Hematology: ANC ≥ 1.5×10⁹/L, Hb ≥ 80 g/L, PLT ≥ 50×10⁹/L
  • Liver function: TBIL ≤ 1.5×ULN, AST/ALT ≤ 5.0×ULN, ALB ≥ 28 g/L
  • Coagulation function: INR, PT or aPTT ≤ 1.5×ULN
  • Renal function: SCr ≤ 1.5×ULN or creatinine clearance ≥ 60 mL/min
  • Urine protein ≤ 1+ or 24-hour urine protein < 1.0 g
  • Cardiac function: LVEF ≥ 50%
  • Females of childbearing potential with negative pregnancy test within 3 days before first dosing
  • Fertile male and female patients agree to effective contraception from screening to 120 days after last study drug
  • HBV/HCV infected patients receive stable antiviral therapy without drug interaction

Exclusion Criteria:

  • Active or untreated CNS metastases; inadequately controlled metastatic brain or leptomeningeal disease
  • Uncontrolled tumor-related pain
  • Thromboembolic disease, ascites or lower limb edema within 6 months
  • History of other malignancies within 5 years before randomization, except curable low-risk tumors
  • Unresolved adverse toxicities from prior antitumor therapy not recovered to ≤ Grade 1 (CTCAE v5.0), excluding alopecia
  • Pregnant, breastfeeding females or those planning pregnancy during the study
  • Any unstable medical, psychiatric or social condition that may interfere with study participation
  • Positive HIV infection
  • Major surgery within 28 days prior to randomization
  • Severe cardiovascular disease, myocardial infarction, unstable arrhythmia, angina or cerebrovascular events
  • Severe systemic infection within 4 weeks before dosing or active infection requiring systemic anti-infective treatment
  • Impaired gastrointestinal absorption, long-term tube feeding, parenteral nutrition or eating disorders
  • Concomitant use of other appetite-enhancing or weight-stimulating agents
  • Cushing's syndrome, adrenal or pituitary insufficiency, poorly controlled diabetes
  • Uncontrolled hypertension despite oral antihypertensive treatment
  • Esophagogastric varices, severe ulcers, gastrointestinal bleeding, obstruction, perforation or fistula within 6 months
  • Known hypersensitivity to any component of the investigational product
  • Any other condition considered inappropriate for enrollment by the investigator.

Quoted from ClinicalTrials.gov, NCT07565415, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07565415, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07565415